# Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

> **NCT06739044** · PHASE3 · COMPLETED · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 494 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Ozempic®
- **DRUG:** HDG1901

## Key facts

- **NCT ID:** NCT06739044
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-20
- **Primary completion:** 2024-10-11
- **Final completion:** 2025-02-21
- **Target enrollment:** 494 (ACTUAL)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06739044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06739044, "Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06739044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*